progress for gilteritinib and quizartinib for aml in the first-line setting
Published 5 years ago • 307 plays • Length 1:50Download video MP4
Download video MP3
Similar videos
-
2:15
novel agents in trials for aml: quizartinib and gilteritinib
-
2:11
update on phase i/ii study of azacitidine, venetoclax and gilteritinib in patients with flt3 aml
-
3:15
developments in targeted aml therapies: venetoclax, quizartinib & gilteritinib
-
2:35
quizartinib for frontline flt3-itd aml: updated results from the quantum-first trial
-
3:31
update on quantum-first: quizartinib soc chemotherapy & as continuation therapy in flt3-itd aml
-
0:57
potential approval of quizartinib in aml & its place in the aml treatment regimen
-
1:59
tangible benefit for flt3-itd r/r aml on quizartinib
-
2:15
real-world analysis of gilteritinib for r/r flt3-mutated aml
-
5:56
hematologic system examination
-
11:06
how could new treatment options improve outcomes in flt3-mutated aml?
-
29:51
finding the key to better outcomes in flt3-mutated aml
-
1:23
the promise of combining venetoclax with gilteritinib for the treatment of flt3-mutated aml
-
3:42
further analysis of quantum-first: the impact of allo-hct combined with quizartinib in flt3-itd aml
-
1:07
quantum-first: the benefit of quizartinib based on pre-transplant mrd status
-
5:24
safety by treatment phase and age when treating flt3-itd-mutated aml with quizartinib and chemo
-
2:27
gilteritinib maintenance after allogeneic transplantation in flt3-mutated aml
-
1:43
lba: gilteritinib as post-transplant maintenance therapy in flt3-itd aml
-
3:03
preclinical data for quizartinib plus mdm2 inhibitor in aml
-
0:54
study design for persist-2 and other upcoming trials of pacritinib
-
2:46
update of the admiral trial: gilteritinib vs salvage chemotherapy prior to hsct in flt-3 mutated aml
-
2:51
ruxolitinib in combination with abemaciclib for patients with primary or post-pv/et myelofibrosis
-
1:08
the progress of the ebmt & key ongoing projects